RE: Positive uptick6 Oct 2025 10:45
From last week, a brief mention of Kmk
Growth opportunities mount for molecular imaging
Sarah Jane James Headshot
Sarah-Jane James
Sep 29, 2025
The introduction of digital technology, primarily digital PET and digital SPECT technologies, has increased scan sensitivity, resolution, and capabilities. In competition with “legacy” technology, digital counterparts are winning most replacement deals across mature regions. Furthermore, the market is still expanding for legacy counterparts in emerging markets due to cost and sufficient capabilities, particularly for theranostics. The digital SPECT cadmium zinc telluride (CZT)-based replacement trend is promoting technology-driven replacement demand in particular; in response, vendors are actively refreshing their product lines and partnering with companies to introduce digital products. Siemens Healthineers’ partnership with Kromek for CZT-based detectors is a prime example.
Looking to the future
The molecular imaging market is entering a new phase of opportunity, underpinned by technology innovation, reimbursement reform, and geographic expansion. While challenges such as isotope fragility, stretched replacement cycles, and reimbursement complexities remain, they are increasingly outweighed by structural growth factors.
Digital PET and Digital CZT-based SPECT are reshaping the competitive landscape in mature markets, while policy support, domestic vendor momentum, and capacity build-outs in APAC are creating entirely new demand pools. Taken together, these forces set the stage for sustained growth at a projected 6.9% over the next five years, making molecular imaging one of the most resilient and strategically important segments in the medical imaging market. Vendors, investors, and providers that align with these trends will be best placed to capture the market’s next wave of growth.
Sign In
Follow the stocks
